JMJD8 reduces cancer's STING.

Area of Science:

• Immunology
• Molecular Biology
• Cancer Research

Background:

• The STING (stimulator of interferon genes) pathway is a critical component of the innate immune system, detecting cytosolic DNA and initiating inflammatory responses.
• Dysregulation of STING signaling is implicated in various diseases, including cancer and autoimmune disorders.
• Understanding regulators of STING signaling is essential for developing novel cancer immunotherapies.

Purpose of the Study:

• To investigate the role of JMJD8 (Jumonji domain-containing protein 8) in regulating STING-dependent immune responses.
• To determine the impact of JMJD8 on antitumor immunity.

Main Methods:

• Utilized cell-based assays to examine the interaction between JMJD8 and STING.
• Employed genetic manipulation (e.g., knockout/knockdown) of JMJD8 in cancer cells and immune cells.
• Assessed STING pathway activation using reporter assays and cytokine measurements.
• Evaluated antitumor immune responses in preclinical cancer models.

Main Results:

• JMJD8 was found to directly inhibit STING signaling.
• Loss of JMJD8 led to enhanced STING activation and increased production of type I interferons.
• JMJD8 deficiency resulted in augmented antitumor immune responses and improved tumor control in vivo.
• JMJD8 acts as a negative regulator of the STING pathway.

Conclusions:

• JMJD8 negatively regulates STING signaling, thereby dampening innate immune responses against tumors.
• Targeting JMJD8 could represent a potential strategy to enhance cancer immunotherapy by boosting STING-dependent antitumor immunity.